A 61-year-old man known to have metastatic prostate adenocarcinoma was seen at Changi General Hospital, Singapore, because of severe hypokalaemia due to ACTH dependent Cushing’s syndrome. He underwent a Dotate PET CT which showed increased DOTA-NOC-avidity in the right side of the prostate gland. Subsequent immunohistochemical staining of prostate biopsy sample documented ACTH, synaptophysin and CD 56 positivity. He was suggested medical management for prostate cancer complicated by Cushing's syndrome. Unfortunately, Cushing’s syndrome was not controlled and the patient’s clinical condition progressively worsened. Subsequently, he developed fatal sepsis due to immunocompromised state. This case report describes a case of Cushing’s syndrome due to metastatic adenocarcinoma of the prostate, a tumour with very few therapeutic options and negative prognosis. JCMCTA 2020 ; 31 (1) : 125-129
Diabetes is a well-known cardiovascular risk factor in both T1DM and T2DM. They have a 4-10 higher risk of developing complications from CVD than the non-diabetic population. The importance of intensive glycaemic control to prevent CVD in T1DM was established in both “The Diabetes Control and Complication Trial” (DCCT) and “Epidemiology of Diabetes Intervention and Complications” (EDIC) trials. Despite the epidemiological evidence that poor glycaemic control can lead to higher incidence of cardiovascular events in T2DM, the intervention trials are still inconclusive. In this report we will highlight the pathophysiology of the effect of hyperglycemia on the cardiovascular system, the effect of medications, and the major Randomized Control Trials (RCTs) looking specifically at the cardiovascular outcome of intensive glycaemic control in T2DM. Chatt Maa Shi Hosp Med Coll J; Vol.19 (2); July 2020; Page 50-56
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.